Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGWP.L Regulatory News (GWP)

  • There is currently no data for GWP

Blocklisting Interim Review

17 Aug 2011 15:29

RNS Number : 5538M
GW Pharmaceuticals PLC
17 August 2011
 

 

 

BLOCKLISTING INTERIM REVIEW

 

1. NAME OF COMPANY:

 

GW PHARMACEUTICALS PLC

 

2. NAME OF SCHEME:

 

GW PHARMACEUTICALS APPROVED COMPANY SHARE OPTION SCHEME

 

3. PERIOD OF RETURN:

 

FROM: 17 FEBRUARY 2011 TO: 17 AUGUST 2011

 

4. NUMBER AND CLASS OF SHARES(S) (AMOUNT OF STOCK/DEBT SECURITY) NOT ISSUED UNDER SCHEME AT END OF THE LAST PERIOD:

 

77,900 ORDINARY SHARES OF 0.1P EACH

 

5. NUMBER OF SHARES ISSUED/ALLOTTED UNDER SCHEME DURING PERIOD:

 

77,900 ORDINARY SHARES OF 0.1P EACH

 

6. BALANCE UNDER SCHEME NOT YET ISSUED/ALLOTTED AT END OF PERIOD:

 

NIL ORDINARY SHARES OF 0.1P EACH

 

7. NUMBER AND CLASS OF SHARE(S) (AMOUNT OF STOCK/DEBT SECURITIES) ORIGINALLY LISTED AND THE DATE OF ADMISSION:

 

507,146 ORDINARY SHARES OF 0.1P EACH ON 7 OCTOBER 2003

 

PLEASE CONFIRM TOTAL NUMBER OF SHARES IN ISSUE AT THE END OF THE PERIOD IN ORDER FOR US TO UPDATE OUR RECORDS.

 

133,000,354 ORDINARY SHARES OF 0.1P EACH

 

 

 

BLOCKLISTING INTERIM REVIEW

 

1. NAME OF COMPANY:

 

GW PHARMACEUTICALS PLC

 

2. NAME OF SCHEME:

 

GW PHARMACEUTICALS APPROVED SHARE OPTION SCHEME 2001

 

3. PERIOD OF RETURN:

 

FROM: 17 FEBRUARY 2011 TO: 17 AUGUST 2011

 

4. NUMBER AND CLASS OF SHARES(S) (AMOUNT OF STOCK/DEBT SECURITY) NOT ISSUED UNDER SCHEME AT END OF THE LAST PERIOD:

 

282,958 ORDINARY SHARES OF 0.1P EACH

 

5. NUMBER OF SHARES ISSUED/ALLOTTED UNDER SCHEME DURING PERIOD:

 

115,870 ORDINARY SHARES OF 0.1P EACH

 

6. BALANCE UNDER SCHEME NOT YET ISSUED/ALLOTTED AT END OF PERIOD:

 

367,088 ORDINARY SHARES OF 0.1P EACH

 

7. NUMBER AND CLASS OF SHARE(S) (AMOUNT OF STOCK/DEBT SECURITIES) ORIGINALLY LISTED AND THE DATE OF ADMISSION:

 

516,558 ORDINARY SHARES OF 0.1P EACH ON 21 JULY 2004

200,000 ORDINARY SHARES OF 0.1P EACH ON 23 FEBRUARY 2011

 

PLEASE CONFIRM TOTAL NUMBER OF SHARES IN ISSUE AT THE END OF THE PERIOD IN ORDER FOR US TO UPDATE OUR RECORDS.

 

133,000,354 ORDINARY SHARES OF 0.1P EACH

 

 

BLOCKLISTING INTERIM REVIEW

 

1. NAME OF COMPANY:

 

GW PHARMACEUTICALS PLC

 

2. NAME OF SCHEME:

 

GW PHARMACEUTICALS UNAPPROVED SHARE OPTION SCHEME 2001

 

3. PERIOD OF RETURN:

 

FROM: 17 FEBRUARY 2011 TO: 17 AUGUST 2011

 

4. NUMBER AND CLASS OF SHARES(S) (AMOUNT OF STOCK/DEBT SECURITY) NOT ISSUED UNDER SCHEME AT END OF THE LAST PERIOD:

 

618,659 ORDINARY SHARES OF 0.1P EACH

 

5. NUMBER OF SHARES ISSUED/ALLOTTED UNDER SCHEME DURING PERIOD:

 

906,592 ORDINARY SHARES OF 0.1P EACH

 

6. BALANCE UNDER SCHEME NOT YET ISSUED/ALLOTTED AT END OF PERIOD:

 

212,067 ORDINARY SHARES OF 0.1P EACH

 

7. NUMBER AND CLASS OF SHARE(S) (AMOUNT OF STOCK/DEBT SECURITIES) ORIGINALLY LISTED AND THE DATE OF ADMISSION:

 

1,279,192 ORDINARY SHARES OF 0.1P EACH ON 21 JULY 2004

500,000 ORDINARY SHARES OF 0.1P EACH ON 24 MAY 2011

 

PLEASE CONFIRM TOTAL NUMBER OF SHARES IN ISSUE AT THE END OF THE PERIOD IN ORDER FOR US TO UPDATE OUR RECORDS.

 

133,000,354 ORDINARY SHARES OF 0.1P EACH

 

 

BLOCKLISTING INTERIM REVIEW

 

1. NAME OF COMPANY:

 

GW PHARMACEUTICALS PLC

 

2. NAME OF SCHEME:

 

GW PHARMACEUTICALS EXECUTIVE SHARE OPTION SCHEME

 

3. PERIOD OF RETURN:

 

FROM: 17 FEBRUARY 2011 TO: 17 AUGUST 2011

 

4. NUMBER AND CLASS OF SHARES(S) (AMOUNT OF STOCK/DEBT SECURITY) NOT ISSUED UNDER SCHEME AT END OF THE LAST PERIOD:

 

NIL ORDINARY SHARES OF 0.1P EACH

 

5. NUMBER OF SHARES ISSUED/ALLOTTED UNDER SCHEME DURING PERIOD:

 

350,400 ORDINARY SHARES OF 0.1P EACH

 

6. BALANCE UNDER SCHEME NOT YET ISSUED/ALLOTTED AT END OF PERIOD:

 

349,600 ORDINARY SHARES OF 0.1P EACH.

 

7. NUMBER AND CLASS OF SHARE(S) (AMOUNT OF STOCK/DEBT SECURITIES) ORIGINALLY LISTED AND THE DATE OF ADMISSION:

 

1,388,375 ORDINARY SHARES OF 0.1P EACH ON 7 OCTOBER 2003

300,000 ORDINARY SHARES OF 0.1P EACH ON 23 APRIL 2008

400,000 ORDINARY SHARES OF 0.1P EACH ON 18 JANUARY 2010

400,000 ORDINARY SHARES OF 0.1P EACH ON 23 FEBRUARY 2011

300,000 ORDINARY SHARES OF 0.1P EACH ON 24 MAY 2011

 

PLEASE CONFIRM TOTAL NUMBER OF SHARES IN ISSUE AT THE END OF THE PERIOD IN ORDER FOR US TO UPDATE OUR RECORDS.

 

133,000,354 ORDINARY SHARES OF 0.1P EACH

 

1. NAME OF COMPANY:

 

GW PHARMACEUTICALS PLC

 

2. NAME OF SCHEME:

 

GW PHARMACEUTICALS LONG TERM INCENTIVE PLAN 2008

 

3. PERIOD OF RETURN:

 

FROM: 17 FEBRUARY 2011 TO: 17 AUGUST 2011

 

4. NUMBER AND CLASS OF SHARES(S) (AMOUNT OF STOCK/DEBT SECURITY) NOT ISSUED UNDER SCHEME AT END OF THE LAST PERIOD:

 

NIL ORDINARY SHARES OF 0.1P EACH

 

5. NUMBER OF SHARES ISSUED/ALLOTTED UNDER SCHEME DURING PERIOD:

 

NIL ORDINARY SHARES OF 0.1P EACH

 

6. BALANCE UNDER SCHEME NOT YET ISSUED/ALLOTTED AT END OF PERIOD:

 

600,000 ORDINARY SHARES OF 0.1P EACH.

 

7. NUMBER AND CLASS OF SHARE(S) (AMOUNT OF STOCK/DEBT SECURITIES) ORIGINALLY LISTED AND THE DATE OF ADMISSION:

 

600,000 ORDINARY SHARES OF 0.1P EACH ON 23 FEBRUARY 2011

 

PLEASE CONFIRM TOTAL NUMBER OF SHARES IN ISSUE AT THE END OF THE PERIOD IN ORDER FOR US TO UPDATE OUR RECORDS.

 

133,000,354 ORDINARY SHARES OF 0.1P EACH

 

 

 

 

For further information, please contact:

 

Adam George, Company Secretary, GW Pharmaceuticals plc

 

Telephone: +44 (0)1980 557000

 

James Steel/Vijay Barathan, Nominated Adviser, Peel Hunt LLP

 

Telephone: +44 (0)20 7418 8900

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BLRZDLFFFVFLBBD
Date   Source Headline
15th Dec 20113:19 pmRNSAnnual Report & Accounts & Notice of AGM
12th Dec 20117:00 amRNSGW Director Wins Wellcome Medal
5th Dec 20113:16 pmRNSDirector/PDMR Shareholding
22nd Nov 20117:00 amRNSFinal Results
22nd Nov 20117:00 amRNSAPPLICATION TO EXPAND SATIVEX® EUROPEAN APPROVALS
17th Nov 20117:00 amRNSEUROPEAN PATENT GRANTED FOR SATIVEX® FORMULATION
24th Oct 201111:00 amRNSSativex Phase III data presented at ECTRIMS
12th Oct 201111:05 amRNSDirector/PDMR Shareholding
5th Oct 20112:51 pmRNSHolding(s) in Company
5th Oct 20112:50 pmRNSHolding(s) in Company
3rd Oct 201112:30 pmRNSDirector/PDMR Shareholding
14th Sep 20117:00 amRNSDirector/PDMR Shareholding
31st Aug 201110:02 amRNSHolding(s) in Company
31st Aug 201110:01 amRNSHolding(s) in Company
17th Aug 20113:29 pmRNSBlocklisting Interim Review
18th Jul 20117:00 amRNSSativex Regulatory Approval
11th Jul 20114:40 pmRNSSecond Price Monitoring Extn
11th Jul 20114:35 pmRNSPrice Monitoring Extension
4th Jul 20117:00 amRNSSativex® launched in Germany
30th Jun 20114:53 pmRNSDirector/PDMR Shareholding
30th Jun 20117:00 amRNSSecond Phase III Pain Trial Commences
8th Jun 20115:01 pmRNSDirector/PDMR Shareholding
8th Jun 20113:01 pmRNSDirector/PDMR Shareholding
8th Jun 20117:00 amRNSRegulatory Approval
3rd Jun 201111:00 amRNSDirector/PDMR Shareholding
26th May 20117:00 amRNSRegulatory Approval
18th May 20111:14 pmRNSBlocklisting Application
17th May 20117:00 amRNSHalf Yearly Report
28th Apr 20117:00 amRNSNotice of Results - Amendment
27th Apr 20115:59 pmRNSNotice of Results
20th Apr 20117:00 amRNSUS Patent Granted for Sativex in Cancer Pain
15th Apr 20117:00 amRNSRegulatory Approval
11th Apr 20117:00 amRNSExclusive Licence Agreement Signed with Novartis
25th Mar 20114:40 pmRNSSecond Price Monitoring Extn
25th Mar 20114:35 pmRNSPrice Monitoring Extension
25th Mar 20114:15 pmRNSDirector/PDMR Shareholding
22nd Mar 20117:00 amRNSSativex Mutual Recognition Procedure Closes
15th Mar 20114:40 pmRNSSecond Price Monitoring Extn
15th Mar 20114:35 pmRNSPrice Monitoring Extension
14th Mar 20117:00 amRNSSativex launched in Spain
2nd Mar 20117:00 amRNSPositive Sativex Study in MS Spasticity Published
22nd Feb 20118:23 amRNSHolding(s) in Company
17th Feb 20115:47 pmRNSBlocklisting Application
17th Feb 20115:46 pmRNSBlocklisting Interim Review
17th Feb 20115:42 pmRNSIssue of Equity
17th Feb 20117:00 amRNSSativex granted reimbursement in Spain
9th Feb 201110:25 amRNSDirector/PDMR Shareholding
19th Jan 20115:05 pmRNSAGM Resolutions passed
17th Jan 20117:00 amRNSReceipt of Milestone Payment
20th Dec 20109:29 amRNSAdviser - Change of Name

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.